This study systematically deciphers the IL4-driven type 2 inflammatory network in asthma, providing critical theoretical foundations for asthma immunophenotyping and biologics development, and guiding mechanistic validation of Th2 cells and ILC2s in experimental design.
Literature Overview
This article, 'Mechanisms and therapeutic strategies of asthma: from bench to bedside,' published in Signal Transduction and Targeted Therapy, systematically explores the genetic, epigenetic, and environmental interactions underlying asthma, and deeply analyzes the complete pathway from epithelial cell ‘alarmin’ release to downstream immune cell network activation. The study further integrates clinical advances of biologics targeting cytokines such as IL4, IL5, IL-33, and TSLP, proposing a novel paradigm of individualized treatment guided by ‘treatable traits.’ The article emphasizes the central role of precision medicine in managing refractory asthma, promoting a shift from symptom control to disease modification.Background Knowledge
Asthma is a highly heterogeneous chronic airway disease with a rising global prevalence, particularly associated with high mortality in low-income countries due to misdiagnosis and inadequate treatment. Current asthma therapy primarily relies on inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA), yet a large proportion of patients, especially those with non-type 2 inflammatory phenotypes (such as neutrophilic or obesity-related asthma), respond poorly to ICS, representing a significant unmet clinical need. The core bottleneck lies in the lack of precise identification and targeted intervention strategies for different endotypes. Recently, Th2 cell-mediated type 2 inflammation has been established as the central driver in most allergic asthma cases, where IL4 and IL13 activate the JAK–STAT pathway to induce B-cell class switching to IgE, and promote mucus hypersecretion and airway remodeling. However, the dynamic regulation of IL4 signaling across asthma subtypes, its crosstalk mechanisms with other alarmins (such as TSLP and IL-33), and its applicability as a therapeutic target remain key research frontiers. Furthermore, gene-environment interactions (such as ORMDL3 with viral infection and CD14 with farm exposure) further increase phenotypic complexity, necessitating integration of multi-omics data for precise subtyping.
Research Methods and Experiments
The authors integrated multi-level evidence from genome-wide association studies (GWAS), epigenome-wide association studies (EWAS), and microbiome research through systematic literature review. Using genetic data from asthma cohorts, they analyzed the functional impacts of key risk loci such as 17q21 (containing ORMDL3, GSDMB) and 5q22 (TSLP), combining eQTL and methylation data to reveal their regulatory effects on epithelial cell function. The study also incorporated single-cell RNA sequencing data to dissect the activation states of Th2 cells, ILC2s, eosinophils, and other cells across different asthma endotypes. For animal models, various gene knockout mice (e.g., IL4-/-, IL13-/-) and humanized mouse models were referenced to validate the therapeutic efficacy of IL4R blockade. Clinical evidence was drawn from multiple phase III trials (e.g., CALIMA, SIROCCO), evaluating the efficacy of anti-IL4Rα antibodies (such as dupilumab) in patients with varying blood eosinophil levels.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a clear target prioritization framework for drug development, advancing the shift from ‘one-size-fits-all’ treatment to biomarker-based precision interventions. Anti-IL4Rα monoclonal antibodies are already widely used clinically, and future applications may integrate multi-omics subtyping to optimize patient selection. Meanwhile, the JAK–STAT pathway, a downstream node of IL4 signaling, is being explored through small-molecule inhibitors (e.g., JAK1 inhibitors) in inhaled formulations to reduce systemic toxicity, showing high translational potential.
In clinical monitoring, FeNO and blood eosinophil counts are already practical biomarkers of type 2 inflammation, but more accurate predictive models should integrate IL4R genotype and microbiome features. Moreover, asthma's heterogeneity demands disease models that more closely mimic human pathology, such as humanized mice or organoid systems, to simulate epithelial-immune crosstalk and airway remodeling, thereby enhancing the clinical predictability of drug screening.
Conclusion
This study comprehensively integrates the latest advances in asthma, from genetic susceptibility to environmental triggers, and from molecular mechanisms to clinical treatments, establishing the central role of the IL4 signaling axis in type 2 inflammation. By emphasizing ‘treatable traits’ and endotype-directed therapeutic strategies, it provides a systematic framework for bench-to-bedside translation. In the future, integrating multi-omics data with artificial intelligence models may enable dynamic risk stratification and personalized interventions for asthma patients. Biologics targeting IL4Rα have significantly improved outcomes for patients with moderate-to-severe type 2 inflammation, while exploration of non-type 2 inflammatory phenotypes still relies on single-cell technologies and microbiome interventions. Ultimately, combining environmental control, early immune modulation, and precision therapeutics will advance asthma care from symptom management toward disease modification and potential remission, improving long-term control for patients worldwide.
